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A B S T R A C T
Purpose
Little is known about change in quality of life (QOL) among long-term cancer survivors. We
examined change over time in QOL among long-term survivors of non-Hodgkin lymphoma and
identified demographic, clinical, and psychosocial risk factors for poor outcomes.
Methods
Surveys were mailed to 682 lymphoma survivors who participated in a study 5 years earlier, when
on average they were 10.4 years postdiagnosis. Standardized measures of QOL, perceptions of
the impact of cancer, symptoms, medical history, and demographic variables were reported at
both time points and examined using linear regression modeling to identify predictors of QOL
over time.
Results
A total of 566 individuals participated (83% response rate) who were a mean of 15.3 years
postdiagnosis; 52% were women, and 87% were white. One third of participants (32%) reported
persistently high or improved QOL, yet a notable proportion (42%) reported persistently low or
worsening QOL since the earlier survey. Participants who received only biologic systemic therapy
reported improvement in physical health despite the passage of time. Older age, more comor-
bidity, and more or increasing negative and decreasing positive perceptions of cancer’s impact
were independent predictors of poor QOL. Lymphoma symptom burden, less social support, and
having received a transplantation were related to negative perceptions of cancer’s impact.
Conclusion
Moderate to severe symptom burden, limited social support, or having received a transplantation
should alert the clinician to potential need for supportive services. Perceptions of cancer’s impact
are associated with QOL cross-sectionally and longitudinally; modifying these perceptions may
thus provide a strategy for improving QOL.
J Clin Oncol 31:272-279. © 2012 by American Society of Clinical Oncology
INTRODUCTION
With an estimated 70,130 new patients in 2012,
non-Hodgkin lymphoma (NHL) is one of the
most common types of cancer.1 Advances in NHL
treatment have resulted in a two-fold improve-
ment in the 5-year survival rate, from 31% among
whites in 1960 to 1963 to 67% for all races in 1999
to 2006. There are approximately 502,940 indi-
viduals in the United States living with a history
of NHL.2
Given its high incidence and survival rates,
NHL can be viewed as a prevalent chronic illness
characterized by alternating symptom-free and
symptom exacerbation phases that may require
treatment. To the clinician, NHL represents a broad
distribution of illness trajectories encompassing ev-
erything from the slow but persistent patterns of
indolent lymphomas to the fast-growing aggressive
lymphomas.3 To the patient, NHL is typically expe-
rienced as a chronic disease that powerfully af-
fects life.4-6
Throughout the illness, attending to survivor-
ship concerns is an important part of cancer care.
Ideally, good survivorship care optimizes the pa-
tient’s quality of life (QOL) within the context of his
or her disease.7 To improve QOL, health services for
NHL must target disease- and treatment-associated
sequelae that impact patients throughout survivor-
ship, potentially diminishing their QOL; an under-
standing of these sequelae is needed to guide health
services planning.8 However, NHL survivors are an
understudied group. Little is known about the lon-
gitudinal effects of recurrence and/or systemic treat-
ment on QOL-related outcomes such as health
and functioning.
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To begin to address this gap, we surveyed a large NHL cohort in
2005 and 2010, focusing on symptoms of post-traumatic stress disor-
der (PTSD),9 QOL,10 and perceptions of the cancer experience as
assessed by the Impact of Cancer (IOC) scale.11,12 The initial cohort
was comprised of NHL survivors diagnosed at least 2 years before the
2005 survey, among whom 39% reported clinically significant PTSD
symptoms and mental health status scores generally below age-
stratified population norms. Longitudinal analyses of PTSD symp-
toms between 2005 and 2010 demonstrated that symptoms persisted
or worsened for 37% of the sample.13 This finding prompted interest
in describing change in QOL over time for NHL survivors.
The current article presents the longitudinal change in QOL-
related outcomes among the respondents to the second survey in
2010, who were all at least 7 years postdiagnosis. A principal interest
was to describe change in QOL experienced by these patients and
identify individuals at risk for worsening QOL, with the goal of pro-
viding practical information to guide the development of survivorship
care interventions. We focused on physical and mental health status as
key QOL-related outcomes and hypothesized that these would remain
poor and/or worsen for a subset of the NHL survivors who had select
demographic (eg, less education) or clinical (eg, more comorbidity)
characteristics or less social support, as informed by prior research.12
After determining that negative patient experience predicted QOL, we
expanded our analyses to identify the risk factors for poor IOC scores.
In addition, we included an examination of systemic treatment status
to better inform clinical care.
METHODS
Study Design and Participants
This follow-up survey built on a prior study that examined QOL-related
outcomes among NHL survivors identified from two academic medical center
cancer registries (Duke University and University of North Carolina). In the
initial cross-sectional study conducted in 2005, 886 participants completed a
mail-in self-report survey that assessed PTSD symptoms, physical and mental
health status, positive and negative IOC, lymphoma symptoms, types of treat-
ment, disease status, and other outcomes. Details about the methods were
previously published.9
The consent form from the original study included a statement of will-
ingness to be recontacted within the next 5 years, which could be endorsed by
the study participant. Considering that eligible patients (in 2005) had to have
been diagnosed with NHL at least 2 years previously and be at least 18 years old,
at recontact in 2010, they were at least 7 years postdiagnosis and  23 years old.
Institutional review boards at Duke University and the University of North
Carolina approved the study. Detailed follow-up survey procedures were pre-
viously published.13
Instruments and Measures
To assess QOL, the Medical Outcomes Study Short Form-36 (SF-36;
version 2.0) was used; this general health measure contains 36 items that are
grouped into eight subscales and two summary scores, the Physical Compo-
nent Score (PCS; Physical Functioning, Role-Physical, Bodily Pain, and Gen-
eral Health) and Mental Component Score (MCS; Vitality, Social
Functioning, Role-Emotional, and Mental Health). The QualityMetric Health
Outcomes scoring software (QualityMetric, Lincoln, RI) was used, where 50
(standard deviation [SD], 10) represents the average (normed) score for each
subscale and summary scale.14
Psychosocial status was assessed with two measures. The 20-item Medi-
cal Outcomes Study Social Support survey has a standardized score ranging
from 20 to 100; higher scores represent better social support.15 The 37-item
IOC (version 2) enables assessment of the patient’s perceptions of positive life
changes resulting from and negative impacts attributed to the cancer experi-
ence.11 The IOC contains four subscales quantifying positive perceptions
(Altruism/Empathy, Health Awareness, Meaning of Cancer, and Positive Self-
Evaluation) and four subscales quantifying negative perceptions (Appearance
Concerns, Body Change Concerns, Life Interferences, and Worry); the mean
of the subscales yield a Positive Impact Summary score and Negative Impact
Summary score, respectively (range, 1 to 5 on each). Higher scores on the
Positive Impact Summary indicate greater positive perceptions of the cancer
experience; higher scores on the Negative Impact Summary indicate greater
negative perceptions.
Demographics and clinical characteristics (eg, income, lymphoma recur-
rence, disease and treatment status) were collected via self-report. To assess the
presence/extent of nonlymphoma clinical conditions, the 15-item Self-
Administered Comorbidity Questionnaire, a self-report version of the Charl-
son comorbidity index, was used.16 Up to three points can be scored for each
medical condition (1 point each for the problem, treatment, and functional
limitation). Lymphoma symptoms such as fevers and night sweats were
captured using the 15-item Functional Assessment of Cancer Therapy–
Lymphoma module.17
Statistical Analysis
To compare follow-up study participants and nonparticipants with re-
spect to initial demographic, clinical, and psychosocial characteristics and
QOL, we tested for differences between responders and both nonresponders
and decedents using t tests for continuous measures and 2 tests for categorical
measures. Computation of PCS and MCS scores consists of multiplying each
SF-36 z score by its respective physical and mental factor score coefficient and
summing the eight subscales, respectively, and then transforming each com-
ponent score to the norm-based scoring based on the 1998 general US popu-
lation mean. To permit comparison to age-related norms, the expected change
in PCS score for each study participant was calculated and then summed and
averaged to generate the expected PCS score for each treatment group.14 To
depict change over time in QOL scores, a participant was assigned to an initial
and follow-up category based on distance from the national age-based PCS
and MCS norms. PCS and MCS scores less than, within, and greater than 0.5
SD of the norm indicated low, medium, and high categories, respectively.18
To assess the association between the demographic, clinical, and psycho-
social characteristics and the follow-up SF-36 or IOC, we used a series of linear
regression models, controlling for initial SF-36 or IOC. We first tested each
characteristic separately (ie, only the candidate measure and initial SF-36 or
IOC score in the model). Then, characteristics that were at least marginally
significantly associated with follow-up SF-36 or IOC in these models (P  .10)
were included in a multiple linear regression to estimate the independent
associations of the initial survey predictors and follow-up survey correlates
with follow-up SF-36 and IOC. For the psychosocial measures, change scores
(follow-up score minus initial score) were included in this model rather than
follow-up scores, to enable evaluation of the effect of changes in these measures
independent of initial status. t tests were used to assess for differences between
participants who reported no recurrence of disease and participants who
reported a recurrence or were never in remission. The least squares means were
obtained from analysis of variance models containing study age and remission
status (in addition to treatment status). Data management and statistical
analyses were conducted with SAS Version 9.2 (SAS Institute, Cary, NC).
RESULTS
A total of 566 patients (83% response rate) participated in this
follow-up survey (Fig 1). Among individuals who participated in the
2005 survey and who were assumed not to be dead in 2010, partici-
pants in the 2010 follow-up survey were compared with nonpartici-
pants; follow-up survey participants were more likely to be white, have
an income of more than $30,000, be married, be older, have received
both chemotherapy and biologic therapy, have received systemic
treatment, not have active disease, and have fewer lymphoma-related
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symptoms. Respondents also reported better QOL at the initial survey
(Table 1). In 2005, the mean time since diagnosis for all follow-up
survey participants was 10.4 years (SD, 7.1 years), and the most com-
mon lymphoma-related symptoms reported were tiring easily, trouble
sleeping, worrying about new symptoms, and experiencing significant
pain. The average interval between the initial and follow-up surveys
was 4.8 years (SD, 0.17 years; range, 4.3 to 5.4 years). The mean age and
time since diagnosis in 2010 were 67.4 years (SD, 12.4 years) and 15.2
years (SD, 7.2 years), respectively. The majority of participants
(n  329; 58.1%) were currently receiving care from an oncology or
survivorship clinic at follow-up. Comparison of decedents to the 2005
sample demonstrates they were older, less educated, and had worse
disease at baseline.
Change in QOL-Related Outcomes
Figure 2 shows SF-36 scores at initial and follow-up surveys. All
scores declined significantly (all P  .01), except for the MCS and
Mental Health subscale. PCS and MCS mean scores were 45.0 (SD,
11.0) and 50.0 (SD, 10.9) at follow-up, respectively.
Figure 3 illustrates the change in QOL scores from the initial to
follow-up surveys. Among the 534 participants who completed the
PCS and MCS at both times, 88 (16.5%) and 98 (18.3%) reported
improvement; 314 (58.8%) and 305 (57.1%) reported stability; and
132 (24.7%) and 131 (24.5%) reported worsening in scores, respec-
tively. In total, 42% of patients reported either low physical or mental
QOL, and 32% reported either high physical or mental QOL at a
median of 12.9 years after their diagnosis.
Figure 4 depicts the change in mean QOL scores among several
systemic treatment regimens and compares each systemic treatment
ever received to no systemic treatment. Only the biologic group re-
ported improvement in mean PCS scores over time. The transplanta-
tion group reported a decline in PCS scores that exceeded the change
for other groups. Smaller differences in the change in mean MCS
scores were found between the no systemic treatment and systemic
treatment groups.
Predictors of QOL and IOC
Table 2 lists the results of linear regression models that controlled
for initial QOL and initial QOL plus other demographic, clinical, and
psychosocial variables. Significant predictors of lower PCS at
follow-up in the final model were older age (P  .001), greater comor-
bidity (eg, back pain, high blood pressure, heart disease; P  .006), a
more negative perception of the cancer experience as measured by
IOC at initial survey (P  .001), and increases in negative (P  .001)
and decreases in positive (P  .012) IOC scores. Both negative IOC at
initial survey and increase in negative IOC scores over time were
predictive of lower MCS (both P  .001) in the final model.
Table 3 lists the results of two linear regression models for the
IOC Negative and Positive Impact Summaries, which adjusted for
initial IOC and initial IOC plus other predictors. Having ever
received a transplantation, more NHL-related symptoms, and less
social support were predictive of greater perceptions of cancer
having negatively impacted one’s life at follow-up. Female sex,
younger age, and increases in social support were predictive of
greater positive perceptions.
DISCUSSION
This article describes change in QOL over 5 years among survivors of
NHL and the relationship between QOL and many demographic,
clinical, and psychosocial variables. These results have important clin-
ical implications. First, regarding physical and mental health status,
notable proportions of the sample reported persistently low status
(16.5% and 19.3%, respectively) or worsening status (24.7% and
24.5%, respectively) over the 5-year study period. These trends are
especially concerning when considering patterns of typical follow-up
care. Although patients with persistently low QOL may continue be-
ing seen by a medical provider across the survivorship trajectory,
patients whose QOL is not recognized as problematic early in survi-
vorship but whose QOL steadily deteriorates over time may have
graduated from acute care before their QOL becomes problematic.
This point is supported by the finding that 38% of our follow-up
sample who reported worsening SF-36 scores reported that they no
longer received health care from an oncology or survivorship clinic.
Consequently, they may lack much-needed support at later stages of
survivorship when they have become invisible to the system of care.8,19
Second, because comorbidity and lymphoma symptom scores
were predictive of QOL and negative IOC scores, respectively, inten-
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Fig 1. CONSORT diagram.
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Table 1. Demographics and Clinical Characteristics, Psychosocial Status, and Quality of Life at the Time of the Initial Survey (2005): Comparison of
Patients Who Did and Did Not Participate in the Follow-Up Survey (2010)










PcNo. % No. % No. %
Demographics
Female sex 294 51.9 78 54.2 .633 79 44.9 .102
White race 494 87.3 108 75.0  .001 155 88.1 .783
Income  $30,000 113 22.2 53 41.4  .001 59 37.8  .001
College or postgraduate degree 242 43.6 50 35.7 .091 45 26.6  .001
Married or living with a partner 452 80.4 96 68.1 .001 124 71.3 .011
Age, years  .001  .001
Mean 62.4 56.7 69.5
SD 12.4 15.6 11.7
Clinical characteristicsd
Had an indolent type of lymphoma 270 50.3 76 55.9 .243 99 60.7 .019
Was diagnosed at stage  I 339 68.1 76 62.3 .224 104 71.2 .467
Systemic treatment statuse
Received chemotherapy only 257 45.4 72 50.0 .324 74 42.1 .433
Received biologic therapy only 29 5.1 7 4.9 .898 5 2.8 .206
Received chemotherapy and biologic therapy 108 19.1 16 11.1 .025 39 22.2 .371
Received a transplantation 90 15.9 15 10.4 .098 30 17.1 .719
Did not receive systemic treatment 82 14.5 34 23.6 .008 28 15.9 .643
Was currently receiving treatment 58 10.4 22 15.6 .083 37 21.8  .001
Had active diseasef 47 9.1 20 15.9 .027 42 28.2  .001
Had a recurrence of disease 184 33.2 39 28.7 .317 70 42.7 .001
Time since diagnosis, years .156 .747
Mean 10.4 9.5 10.2
SD 7.1 6.5 7.3
Comorbidity scoreg .166  .001
Mean 5.2 5.8 6.7
SD 4.5 5.5 5.2
Had a second primary cancer 71 12.7 16 11.4 .673 33 19.4 .027
Lymphoma symptom scoreh .001  .001
Mean 49.3 46.3 44.4
SD 8.8 11.5 11.0
Psychosocial status scores
Social Supporti .079 .514
Mean 83.4 80.7 84.3
SD 16.0 17.1 17.3
IOC Negative Impactj .080 .003
Mean 2.2 2.3 2.4
SD 0.7 0.9 0.8
IOC Positive Impactk .978 .181
Mean 3.5 3.5 3.4
SD 0.8 0.8 0.8
Quality-of-life scores
SF-36 PCSl .033  .001
Mean 47.2 45.0 39.1
SD 10.2 11.3 11.5
SF-36 MCSm  .001  .001
Mean 50.4 45.7 45.7
SD 10.7 11.3 11.7
Abbreviations: IOC, Impact of Cancer; MCS, Mental Component Score; PCS, Physical Component Score; SD, standard deviation; SF-36, Medical Outcomes Study Short Form-36.
aAssumed living; calculated as total initial sample (N  866) minus participants (n  566) minus deceased (n  176).
bP value for comparison of participants and nonparticipants, based on 2 for percentages and t test for means.
cP value for comparison of participants and decedents, based on 2 for percentages and t test for means.
dDoes not include changes between baseline and follow-up surveys.
eSystemic treatment at initial survey includes chemotherapy, biologic therapy, and bone marrow or stem-cell transplantation.
fWas not in remission or cured of non-Hodgkin lymphoma.
gSelf-Administered Comorbidity Questionnaire; possible score range, 0 to 42.
hFunctional Assessment of Cancer Therapy–Lymphoma module; 15 items, possible score range, 0 to 60. Lower scores indicate greater symptoms.
iMedical Outcomes Study Social Support total score; possible score range, 0 to 100; higher scores indicate higher support.
jIOC Negative Summary score; possible score range, 1 to 5; higher scores indicate greater negative impacts.
kIOC Positive Summary score; possible score range, 1 to 5; higher scores indicate greater positive impacts.
lThe median population score is 50; a higher score indicates better functioning.
mThe median population score is 50; a higher score indicates better functioning.
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survivors. Our results suggest that the presence of moderate or severe
symptom burden should alert the clinician to a potential need for
psychosocial support. Additionally, symptom control may have a
beneficial effect on QOL-related outcomes. Implementation of sys-
tems to make symptom screening and systematic documentation at
point of care routine can likely support better symptom control.20-23
Third, PCS scores deteriorated to a lesser extent over the 5-year
period than age-related norms might suggest (Fig 4). However, this
may be partly attributed to selection bias, because the more affluent
and able continued to participate (Table 1). Improved PCS scores
reported by patients who received only biologic systemic therapy are
encouraging. Consequently, the treatment (and presumably experi-
ences during these treatment periods) may have implications for in-
tervention. Clinicians might consider proactive comprehensive
survivorship assessment in transplantation populations for appropri-
ate services (eg, physical therapy, pain management, social work).
Fourth, although the mean decline in MCS was nonsignificant,
the directional change was of improvement in emotional well-being
among similar age-related norms over time. For example, the MCS
general population norm for the 65 to 74 year age group is 1.6 points








































Fig 3. Change in quality of life: depiction of Medical Outcomes Study Short Form-36 scores [No. (%)] over 5 years (n  534). High represents at least 0.5 standard
deviation (SD) greater than the age-based norm; medium (Med) represents within 0.5 SD of the age-based norm; and low represents at least 0.5 SD less than the
age-based norm. MCS, Mental Component Score; PCS, Physical Component Score.
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Fig 2. Initial and follow-up norm-based survey scores on the Medical Outcomes
Study Short Form-36 (SF-36) scales (n  534). BP, Bodily Pain; GH, General
Health; MCS, Mental Component Score; MH, Mental Health; PCS, Physical
Component Score; PF, Physical Functioning; RE, Role-Emotional; RP, Role-



































































Fig 4. Change in Medical Outcomes Study Short Form-36 scores over 5 years
by type of systemic treatment ever received (n  534). Biol., biologic; BMT, bone
marrow transplantation; Chemo., chemotherapy; MCS, Mental Component
Score; PCS, Physical Component Score; Trt., treatment.
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studies conducted with breast cancer survivors24,25 and community-
dwelling adults26 reported small improvements in MCS over 5 years.
Because our sample included individuals who reported a recurrence
or active disease, a future study might explore the role of expectancy or
worry in mediating the decrease in emotional health among those with
unremitting disease; if either plays a mediating role, then cognitive-
behavioral approaches such as the Managing Uncertainty Day-to-Day
intervention27 might ameliorate their decline. Although these indo-
lent lymphomas may be viewed as simple cancers given that treatment
is unneeded in some patients, for the patient, they represent a real
cancer and, based on our findings, may justify early/continuous psy-
chosocial intervention(s).
Arguably the most important and clinically meaningful finding
of this study is the identified relationship between the impact of cancer
and QOL. Negative perceptions of the impact of cancer at initial
survey and worsening of negative perceptions from initial survey to
follow-up predicted lower PCS and MCS scores. In separate analyses
(not shown), our data suggest that negative IOC scores mediate the
effects of two clinical measures (chemotherapy and lymphoma symp-
toms) and social support on MCS. The potential implications of these
findings are profound: If we can determine which interventions alter
perceptions of cancer’s impact, then we may have a powerful ap-
proach to sustaining and enhancing QOL among NHL survivors, a
population among which 25% are at risk for longitudinal deteriora-
tion of QOL.
First steps toward modifying the impact of cancer to improve
QOL are to better understand impact (IOC) as a construct and its
relationship to other potentially modifiable factors. Although positive
Table 2. Multiple Linear Regression to Identify Predictors of Quality of Life at Follow-Up
Variable
PCS MCS
Adjusted for Initial PCS
Adjusted for Initial PCS and
Other Predictors (n  519) Adjusted for Initial MCS
Adjusted for Initial MCS and









Initial PCS or MCS 0.74 0.03  .001 0.52 0.04  .001 0.65 0.03  .001 0.47 0.04  .001
Demographicsa
Female sex 0.17 0.69 .807 1.39 0.73 .055 1.03 0.69 .134
Nonwhite race 0.63 1.04 .544 1.42 1.10 .201
Income  $30,000 1.93 0.90 .032 1.21 0.84 .150 1.31 0.96 .173
Less than college degree 0.36 0.72 .616 1.00 0.74 .177
Not married 0.25 0.89 .782 0.09 0.94 .925
Age at study enrollment 0.16 0.03  .001 0.21 0.03  .001 0.01 0.03 .631
Clinical characteristicsb
Years since diagnosis 0.06 0.05 .237 0.004 0.05 .943
Recurrence in last 5 yearsc 0.51 0.73 .485 0.84 0.79 .288
Systemic treatment statusd
Received chemotherapy 0.47 1.03 .651 2.16 1.09 .049 1.36 1.05 .195
Received biologic treatment 1.47 1.76 .404 0.07 1.87 .972 1.65 1.77 .353
Chemotherapy-biologic
therapy interaction
0.14 1.18 .903 2.21 1.25 .078 1.03 1.20 .394
Ever had transplantation 0.34 1.24 .783 1.26 1.32 .339 0.49 1.30 .703
No systemic treatment ever
Comorbidity scoree 0.30 0.10 .002 0.25 0.09 .006 0.23 0.09 .009 0.11 0.09 .220
Lymphoma symptom scoref 0.68 0.47 .143 2.13 0.51  .001 0.58 0.59 .324
Psychosocial statusg
Social Supporth 0.02 0.02 .356 0.06 0.02 .008 0.04 0.02 .096
IOC Negative Impacti 0.80 0.54 .136 3.05 0.53  .001 2.66 0.65  .001 3.70 0.78  .001
IOC Positive Impactj 0.003 0.45 .994 0.0001 0.44 .999 0.65 0.48 .175
 Social support 0.02 0.02 .340 0.03 0.02 .165
 IOC Negative Impact 3.71 0.61  .001 5.21 0.60  .001 3.91 0.65  .001 4.88 0.67  .001
 IOC Positive Impact 1.18 0.61 .052 1.49 0.59 .012 1.05 0.65 .104
Model-adjusted R2 P .48 .59 .41 .50
Abbreviations: IOC, Impact of Cancer; MCS, Mental Component Score; PCS, Physical Component Score.
aDemographic variables are from the 2005 survey.
bClinical variables are from the 2005 survey (years since diagnosis, comorbidity, lymphoma symptom score, and systemic treatment status) and the follow-up 2010
survey (systemic treatment status and recurrence in last 5 years).
cParticipants who reported having a recurrence of their lymphoma within the last 5 years or who have never been in remission.
dMutually exclusive categories; participants reported receiving systemic treatment (ie, chemotherapy, biologic therapy such as rituximab, transplantation) at initial
and/or follow-up survey.
eSelf-Administered Comorbidity Questionnaire; possible score range, 0 to 42.
fFunctional Assessment of Cancer Therapy–Lymphoma module; 15 items, possible score range, 0 to 60. Lower scores indicate greater symptoms.
gPsychosocial variables are from the 2005 survey except for change variables.
hMedical Outcomes Study Social Support total score; possible score range, 0 to 100; higher scores indicate higher support.
iIOC Negative Summary score; possible score range, 1 to 5; higher scores indicate greater negative impacts.
jIOC Positive Summary score; possible score range, 1 to 5; higher scores indicate greater positive impacts.
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and negative IOC scores might seem to represent two ends of a con-
tinuum, prior results related to their positive association with PTSD
suggest that the IOC Positive and Negative Impact Summary scores
measure distinct constructs.13 This may reflect many patients’ ability
to turn lemons into lemonade despite heightened awareness of abun-
dant lemons.
This study had several limitations. First, there is potential for
selection bias. Our sample included predominantly married and white
individuals; however, this racial profile closely mirrors that of the
national population of NHL survivors, thereby strengthening the gen-
eralizability of our findings. Second, individuals who participated in
the survey had fewer symptoms and less active disease than those who
did not participate or were deceased; thus, if results were skewed, the
direction would likely be toward overestimation rather than underes-
timation of QOL during survivorship. Third, in an effort to minimize
respondent burden, the 28-page survey lacked measures assessing
other psychological attributes that might have elucidated protective
mechanisms (eg, optimism, resilience). Fourth, the use of self-
reported clinical status introduces potential error in that participants
may not have thorough understanding of their clinical condition; this
concern was minimized by using standardized instruments. Fifth,
statistical tests were not subject to multiple comparison corrections in
this article. Given the number of tests conducted, a more conservative
significance level could be considered. Thus, some results may be
interpreted cautiously. However, given that we used an a priori plan
informed by theory and empirical data, we feel confident about the
findings, particularly those related to the IOC in our discussion.
In summary, our results suggest that the presence of comorbidity
or symptom burden in NHL survivors should alert the clinician to a
potential need for supportive services. The IOC measure is associated
with QOL-related outcomes cross-sectionally and longitudinally; if
this relationship is causal, modifying IOC may provide a strategy for
improving QOL. And, perhaps most importantly, our results show
that QOL and the cancer experience, and their changes over time, are
complex. Although we can signal specific subpopulations at risk, there
isn’t a one-size-fits-all approach; it is difficult to predict the long-term
Table 3. Multiple Linear Regression to Identify Predictors of IOC at Follow-Up
Variable
Negative Impact Summary Positive Impact Summary
Adjusted for Initial IOC
Negative Impact
Adjusted for Initial IOC
Negative Impact and Other
Predictors (n  549)
Adjusted for Initial IOC
Positive Impact
Adjusted for Initial IOC
Positive Impact and Other









Initial IOC Negative or Positive
Impact 0.78 0.03  .001 0.62 0.04  .001 0.73 0.03  .001 0.72 0.03  .001
Demographicsa
Female sex 0.02 0.04 .729 0.10 0.05 .037 0.12 0.05 .010
Nonwhite race 0.06 0.07 .344 0.006 0.07 .929
Income  $30,000 0.10 0.06 .072 0.07 0.06 .197 0.01 0.06 .850
Less than college degree 0.02 0.05 .726 0.01 0.05 .762
Not married 0.02 0.06 .755 0.09 0.06 .118
Age at study enrollment 0.003 0.002 .056 0.003 0.002 .074 0.004 0.002 .041 0.004 0.002 .036
Clinical characteristicsb
Years since diagnosis 0.001 0.003 .792 0.002 0.003 .595
Recurrence in last 5 yearsc 0.04 0.05 .423 0.05 0.05 .340
Systemic treatment statusd
Received chemotherapy 0.11 0.07 .094 0.13 0.07 .056 0.06 0.07 .412 0.05 0.07 .499
Received biologic treatment 0.12 0.12 .310 0.18 0.12 .126 0.11 0.12 .361 0.12 0.12 .304
Chemotherapy-biologic
therapy interaction 0.14 0.08 .073 0.15 0.08 .058 0.14 0.08 .083 0.13 0.08 .109
Ever had transplantation 0.26 0.08 .002 0.26 0.08 .001 0.16 0.09 .061 0.12 0.09 .180
No systemic treatment ever 
Comorbidity scoree 0.003 0.005 .511 0.003 0.005 .606
Lymphoma symptom scoref 0.15 0.04  .001 0.14 0.04  .001 0.03 0.03 .341
Psychosocial statusg
Social Supporth 0.003 0.001 .020 0.003 0.001 .024 0.0005 0.001 .734 0.001 0.002 .451
 Social Support 0.001 0.002 .652 0.004 0.002 .008 0.004 0.002 .008
Model-adjusted R2 P .50 .54 .52 .55
Abbreviation: IOC, Impact of Cancer.
aDemographic variables are from the 2005 survey.
bClinical variables are from the 2005 survey (years since diagnosis, comorbidity, lymphoma symptom score, and systemic treatment status) and the follow-up 2010
survey (systemic treatment status and recurrence in last 5 years).
cParticipants who reported having a recurrence of their lymphoma within the last 5 years or who have never been in remission.
dMutually exclusive categories; participants reported receiving systemic treatment (ie, chemotherapy, biologic therapy such as rituximab, transplantation) at initial
and/or follow-up survey.
eSelf-Administered Comorbidity Questionnaire; possible score range, 0 to 42.
fFunctional Assessment of Cancer Therapy–Lymphoma module; 15 items, possible score range, 0 to 60. Lower scores indicate greater symptoms.
gPsychosocial variables are from the 2005 survey except for change variables.
hMedical Outcomes Study Social Support total score; possible score range, 0 to 100; higher scores indicate higher support.
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outcome for any particular person. The factors influencing QOL and
their interplay must be monitored, integrating the most up-to-date
analyses from the literature and individual patient experiences, to
personalize psychosocial care. This requires integration of patient-
reported monitoring as a standard of survivorship care using practical
scales that can be efficiently embedded in routine practice and mapped
back to more rigorous research instruments as needed.28
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